Overview

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study is an open, multicenter, dose-escalation and expansion, non-randomized phase II/III clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M11D1 in combination with cytarabine + daunorubicin or venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Treatments:

Azacitidine
Cytarabine
Daunorubicin
venetoclax